VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
PHGKoninklijke Philips N.V.
$27.10$25.8B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPHGCash Flow

Koninklijke Philips N.V. (PHG) Cash Flow Statement

30Y historyFree accessUpdated daily

Cash conversion remains highly erratic, highlighted by a 2025Q1 OCF/NI ratio of -12.92 and free cash flow margins that swung from -25.4% to 25.7% within a single year.

PHG Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96
Cash from Operations2.3B1.16B1.7B2.31B-181.82M1.93B2.64B2.27B1.78B1.87B1.9B1.17B1.3B1.14B2.2B566M2.16B1.54B1.5B1.37B853.92M2.09B2.69B1.99B2.23B1.25B3B1.92B2.22B3.46B1.22B
Operating CF Margin %-6.52%9.42%12.71%-1.02%11.23%15.25%13.26%9.82%10.52%7.77%4.81%6.09%4.88%8.87%2.51%8.48%6.66%5.67%5.1%3.17%6.88%8.89%6.86%7%3.86%7.91%6.08%7.33%10.1%3.81%
Operating CF Growth %454.29%-31.53%-26.51%1370.09%-109.44%-27.02%16.14%27.71%-4.81%-1.79%63.15%-10.44%14.5%-48.23%288.34%-73.75%39.55%3.34%9.26%60.24%-59.12%-22.49%35.53%-10.84%78.43%-58.41%56.58%-13.5%-35.95%184.54%0.24%
Net Income972.48M895M-912.95M-492.99M-1.7B718.64M1.19B1.33B1.31B1.03B1.07B414M221M1.17B262M-776M1.45B410M8M4.17B5.38B2.95B2.83B693.98M-3.21B-2.61B9.63B1.8B6.02B2.57B-272.38M
Depreciation & Amortization1.12B1.13B1.26B1.39B1.26B1.24B1.46B1.09B1.09B1.02B1.27B1.28B1.19B1.35B1.43B1.46B1.42B1.47B1.19B852.54M834.22M1.51B2.29B2.01B2.19B2.8B2.33B1.86B1.88B1.68B1.66B
Stock-Based Compensation94M141M0000112M0102M122M95M82M85M104M80M0000000000000000
Deferred Taxes95M00000284M0193M349M327M239M26M000000000000000000
Other Non-Cash Items488.23M330M1.35B-98.38M1.5B143.02M131M609.99M962M1.46B1.25B382M10M-258M-1.17B1.35B-291M-112M12M-393.52M-5.74B-1.9B-2.43B-197.26M2.69B561.96M-7.75B-1.15B-5.82B-1.06B0
Working Capital Changes-472.98M-1.33B7.57M1.51B-1.24B-179.66M-536M-755.49M-500M-509M-512M-346M540M-1.69B392M-1.17B-509M-222M285M-851.16M-1.38B-364.74M-32.46M-90.52M565.11M494.52M-1.2B-590.31M138.13M168.18M-81.15M
Change in Receivables-20.18M-9M-1.08M322.17M-359.43M092M0-97M64M357M-554M584M-2.1B210M-1.35B0-479M0000000000000
Change in Inventory-96.72M-115M248.79M277.85M-601.16M-686.73M-578M-195.87M-394M-144M44M22M-77M-165M-19M-81M-705M687M41M-389.57M2.27M-195.88M0000-981.69M45.71M-59.69M-213.64M0
Change in Payables-133.89M0-630.63M387.04M54.65M258.85M0-413M00-154M464M-607M769M-233M755M0-479M0000000000000
Cash from Investing-991.68M-737M-633.87M-553.53M-1.58B-317.95M-1.27B-702.89M-1.49B-3.2B-1.17B-1.94B-984M-997M-912M-1.46B-702M-219M-3.1B3.97B3.79B1.3B652.85M740.83M-247.77M-4.57B-2.41B-3.84B3.69B-60.91M-2.08B
Capital Expenditures-475.68M-269M-731.22M-695.16M-847.09M-901.85M-895M-1.13B-843M-859M-869M-957M-846M-993M-1.06B-841M-952M-620M-892M-780.52M-803.15M-996.29M-1.39B-978.24M-1.16B-2.15B-3.18B-1.67B-1.62B-1.67B-2.32B
CapEx % of Revenue2.69%1.51%4.06%3.83%4.75%5.26%5.17%6.61%4.65%4.83%3.54%3.95%3.95%4.26%4.28%3.72%3.75%2.67%3.38%2.91%2.98%3.28%4.58%3.37%3.65%6.63%8.37%5.28%5.36%4.88%7.26%
Acquisitions-223.58M-3M141.7M104.87M-600.11M-3.5B-313M-82.82M-558M-2.28B-171M-1.06B-197M68M-226M-509M-106M-210M-5.29B155.01M-2.15B-1.19B-439.66M-468.48M-626.1M-3.64B-3.22B-3B-862.04M-302.73M-456.37M
Investments-------------------------------
Other Investing-198M-465M27.04M134.06M-12.61M4.02B20M-27.98M-549M-463M-1.11B516M-147M-430M-196M2M129M-101M-3.12B4.56B3.78B2.25B-1.18B2.38B1.54B240.52M-638.84M-251.43M1.04B1.81B695.81M
Cash from Financing132.62M107M-536.52M-916.79M525.49M-2.77B483M-1.86B-1.19B55M-420M508M-1.19B-1.24B-292M-1.79B-96M-545M-3.58B-2.37B-3.71B-2.59B-2.14B-1.35B-897.7M3.16B-2.04B-2.61B-809.17M-2.64B674.11M
Debt Issued (Net)475.44M448M-88.7M-195.68M1.15B-296.68M767M122M126M-217M-1.61B1.25B-264M-122M730M-860M134M60M380M-281.89M-437.19M-323.37M-1.67B-941.72M-419.31M3.96B613.29M-719.5M-445.09M-2.25B1.01B
Equity Issued (Net)20.89M0-444.57M-715.7M-183.92M-1.91B-343M-1.48B-1.04B-642M-526M-506M-596M-562M-768M-671M65M29M-3.26B-1.45B-2.75B-1.76B-17.7M49.23M-19.06M-336.05M-579.22M-37.76M-156.89M-112.73M35.35M
Dividends Paid-328M-328M-1.08M-2.16M-433M-569.71M-1M-507.02M-401M-384M-330M-298M-292M-272M-255M-259M-296M-634M-698M-639.92M-522.81M-503.21M-459.57M-458.95M-459.33M-458.56M-400.34M-361.74M-324.86M-250M-253.09M
Share Repurchases00-444.57M-715.7M-196.53M-1.93B-343M-1.54B-1.04B-642M-606M-506M-713M-669M-768M000-3.26B-1.45B-2.75B-1.76B-17.7M0-19.06M-336.05M-579.22M-37.76M-156.89M-112.73M0
Other Financing-35.71M-13M-2.16M-3.24M-6.31M-2.36M60M-2.24M125M1.3B2.98B81M-37M-285M03M1M00-639.23M-522.81M-844.31K-459.57M-1.59M00-1.68B-1.49B111.7M-14.55M0
Net Change in Cash1.34B393M421.64M813.77M-1.37B-1.33B1.8B-330.07M-251M-395M568M-107M-592M-1.37B687M-2.69B1.45B766M-5.26B2.86B729.66M958.29M1.28B1.21B968.22M-200.06M-1.24B-4.23B5.13B730M-237.83M
Free Cash Flow1.91B893M1.35B1.94B-648.45M1.46B2.15B1.69B937M1.01B1.03B210M457M145M1.14B-275M1.2B925M603M587.79M50.77M1.09B1.31B1.01B1.07B-896.88M-174.62M252.42M594.3M1.79B-1.1B
FCF Margin %10.8%5.01%7.51%10.66%-3.64%8.49%12.45%9.88%5.17%5.69%4.22%0.87%2.14%0.62%4.59%-1.22%4.74%3.99%2.29%2.19%0.19%3.6%4.31%3.48%3.35%-2.77%-0.46%0.8%1.96%5.21%-3.44%
FCF Growth %272.27%-34.06%-30.1%398.77%-144.49%-32.37%27.26%80.73%-7.32%-2.32%392.86%-54.05%215.17%-87.25%513.45%-122.84%30.16%53.4%2.59%1057.86%-95.35%-16.37%29.35%-5.45%219.11%-413.63%-169.18%-57.53%-66.78%262.77%5.52%
FCF per Share1.970.931.452.04-0.681.532.251.740.941.001.050.210.460.151.15-0.271.190.930.570.500.040.820.950.740.79-0.66-0.120.180.431.31-0.78
FCF Conversion (FCF/Net Income)1.97x1.30x-2.42x-4.96x0.11x0.58x2.22x1.95x1.63x1.13x1.31x1.81x3.14x0.97x9.73x-0.44x1.49x3.77x-16.25x0.33x0.16x0.73x0.95x2.87x-0.69x-0.48x0.31x1.06x0.37x1.35x-4.47x
Interest Paid104M253M00000000000000000000000000000
Taxes Paid0000000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityStrained
Balance SheetStrained
Cash FlowMixed
Top Statement Risk

Litigation and regulatory volatility

Earnings Quality Remains Highly Volatile

As reported in recent financial filings, the relationship between net income and operating cash flow is erratic, highlighted by a 2025Q1 OCF/NI ratio of -12.92, which suggests that accounting profits are frequently decoupled from the actual cash generation capabilities of the underlying medical device business operations.

The extreme variance in conversion ratios indicates that non-cash charges and significant working capital swings are masking the true cash-generating capacity of the firm. Investors should monitor whether these discrepancies are purely related to one-time litigation settlements or if they reflect a structural inability to convert reported earnings into tangible liquidity.

Free Cash Flow Trajectory Unstable

Based on the provided cash flow data, free cash flow margins have fluctuated wildly from a -25.4% trough in 2025Q1 to a 25.7% peak in 2025Q4, indicating that the company's ability to sustain positive cash flow remains highly sensitive to non-recurring operational and legal expenses.

The lack of a consistent FCF growth trend suggests that the business is currently in a defensive posture rather than a value-creation phase. The volatility in these margins implies that the company's cash flow profile is currently dictated more by external remediation costs than by core product performance.

Working Capital Swings Obscure Performance

According to historical cash flow statements, working capital changes have been a major source of volatility, including a massive $1.4 billion outflow in 2025Q1, which suggests that inventory management and collection cycles are currently subject to significant, unpredictable disruptions that impact the firm's immediate liquidity position.

These large swings in working capital often point to difficulties in managing supply chain inventory or delays in receiving payments from hospital systems. Such instability warrants further investigation into whether these are temporary timing differences or evidence of deeper inefficiencies in the company's order-to-cash cycle.

Capital Intensity Remains Elevated

As evidenced by the company's reported figures, capital expenditures have consistently consumed a significant portion of revenue, with CapEx/Rev ratios frequently exceeding 4%, which indicates that the firm must maintain high levels of reinvestment just to sustain its existing medical imaging and diagnostic hardware installed base.

The persistent need for high capital intensity suggests that the company is struggling to transition toward a less asset-heavy, software-driven model. This level of spending may limit the firm's ability to deleverage or return capital to shareholders until the core product portfolio reaches a more stable, mature state.

PHG — Frequently Asked Questions

Quick answers to the most common questions about buying PHG stock.

How much cash does Koninklijke Philips N.V. (PHG) generate from operations?

Koninklijke Philips N.V. (PHG) generated $1.16B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Koninklijke Philips N.V.'s free cash flow?

Koninklijke Philips N.V. (PHG) generated $893.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Koninklijke Philips N.V.'s capital expenditure (CapEx)?

Koninklijke Philips N.V. (PHG) spent $269.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does Koninklijke Philips N.V. distribute cash to shareholders?

In 2025, Koninklijke Philips N.V. (PHG) returned $328.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.